Protective effect of irradiated renal carcinoma expressing hepatitis B surface antigen against renal-cell carcinoma-mediated tumors.
Radiation therapy and chemotherapy have little effect on renal-cell carcinomas (RENCAs). We investigated the effect of the tumor vaccination strategy on preventing tumor formation after a challenge with RENCA. The hepatitis surface antigen (HBsAg) was used to enhance the antitumor immunity and tumor vaccination efficiency. RENCA cells expressing HBsAg (RENCA/HBS) were completely susceptible to HBsAg vaccination, which implies that HBsAg vaccination induces specific antitumor immunity against HBsAg- expressing cancer cells. As with HBsAg vaccination, vaccination with irradiated RENCA/HBS retarded tumor formation following a RENCA/HBS challenge. After HBsAg vaccination, the irradiated RENCA/HBS tumor vaccine completely prevented the tumor formation by RENCA/HBS. Tumor vaccination with irradiated RENCA/HBS (5 x 10(4) cells), but not with RENCA, reduced the tumor rate after a challenge with 5 x 10(6) RENCA cells, whereas a lower tumor load was overcome by the RENCA vaccination alone. These results confirm the postulate that RENCA/HBS vaccination elicits an antitumor immune response to some putative antigens or enhances the general immune competence in immunosuppressed renal tumor patients.
Moon
Yuseok
Y
Department of Microbiology and Immunology, Medical Research Institute, Pusan National University Medical School, Busan, Korea.
Cho
Seok Goo
SG
Lee
Jong Wook
JW
Min
Woo Sung
WS
Kim
Chun Choo
CC
Lee
Hae-Kyung
HK
Kim
Yong-Goo
YG
Chang
Hong Seok
HS
Chae
Hyun Seok
HS
Kim
Ho-Youn
HY
Tani
Kenzaburo
K
D000818:Animals; D019496:Cancer Vaccines / Q000378:metabolism / Q000627:therapeutic use*; D002292:Carcinoma, Renal Cell / Q000532:radiotherapy* / Q000628:therapy; D045744:Cell Line, Tumor; D005260:Female; D006514:Hepatitis B Surface Antigens / Q000096:biosynthesis*; D006801:Humans; D007166:Immunosuppressive Agents / Q000494:pharmacology; D007680:Kidney Neoplasms / Q000532:radiotherapy* / Q000628:therapy; D051379:Mice; D008807:Mice, Inbred BALB C; D009368:Neoplasm Transplantation; D009369:Neoplasms / Q000378:metabolism; D010957:Plasmids / Q000378:metabolism
D019496:Cancer Vaccines; D006514:Hepatitis B Surface Antigens; D007166:Immunosuppressive Agents